Back to mobile site
Get it on Google Play

Veru posts Q3 loss, reports full enrollment in obesity drug trial

August 10, 2026 6:30 AM EDT Send to a Friend
Veru Inc. (NASDAQ: VERU) reported a net loss of $7.0 million, or $0.30 per share, for its fiscal third quarter ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login